Fundraising Fox
RTW Investments L.P.
Venture capitalNew York · Seed–Series A · 14 people tracked
Find your way into RTW Investments L.P.
3,226 people in our graph share verified history with the RTW Investments L.P. team — schools, employers, funds. One of them is your warm intro.
Investment thesis
RTW Investments L.P. is a New York-based venture capital firm investing across the biopharmaceutical and medical technology sectors from early stage through later rounds. The firm partners with companies and academic institutions developing new therapeutic approaches and medical devices.
Source: firm website, verified Sep 22, 2026.
Team · 14 people
from curated & public directories
Founder mafia
2 people who came through RTW Investments L.P. went on to found or lead other companies.
What they invest in
from 31 of 36 portfolio companiesBiotech ×25Healthtech ×19Medical Devices ×11Digital Health ×5Deep Tech ×3AI & Machine Learning ×2Data & Infrastructure ×2Defense Tech ×1
HQs:United States×24China×1
Investments · 36 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 42024 · 32023 · 22022 · 12021 · 42020 · 22019 · 12018 · 32017 · 125 dated
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundPappas CapitalRA Capital+5 more
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Henderson(Chief Executive Officer and Director)in
Co-investorsAccess BiotechnologyRA CapitalBlackstone Life SciencesPerceptive Xontogeny VentureVenrock Healthcare Capital Partners
Aquestive Therapeutics develops and commercializes oral film drug formulations and other novel delivery systems for treatments in neurology, psychiatry, and emergency care, operating manufacturing facilities in Indiana that produce both licensed pharmaceutical products and proprietary candidates for regulated markets including the U.S., EU, and Australia.
BiotechWarren, US
Keith J Kendall(Chief Executive Officer)inA. Mark Shobel(Chief Operating Officer)Theresa Wood(Vice President, Human Resources)inPeter Boyd(Vice President, Value Delivery)Daniel Barber(Vice President, Business and Product Development)inJohn T Maxwell(Chief Financial Officer, Treasurer, Secretary)in
Co-investorsOaktree
Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription.
Digital HealthHealthtechMedical DevicesIrvine, US
Edward Damiano(Executive Officer, Director)Sean Saint(President, Chief Executive Officer and Director)inStephen Feider(Chief Financial Officer)inMike Mensinger(Chief Product Officer)inSteven Russell(Chief Medical Officer)inMark Hopman(Chief Commercial Officer)in
Co-investorsLifeSci Venture PartnersOmega FundsSoleus Capital
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases such as wet AMD, diabetic eye disease, and retinal vein occlusion.
BiotechHealthtechBerkeley Heights, US
Srinivas Akkaraju(Director & Co-founder)Mike Dybbs(Director & Co-founder)inNapoleone Ferrara(Director & Co-Founder)Andrew Oxtoby(CEO & Director)inMatthew Feinsod(CMO)Liisa Bayko(CFO)
Co-investorsSamsara BioCapitalInvus
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesVida VenturesWestlake Village BioPartnersGilead SciencesKleiner PerkinsOxford Finance LLC+1 more
Neurogene develops gene therapy treatments for rare neurological diseases.
BiotechDeep TechDigital HealthLongevityMedical DevicesNew York, US
Rachel McMinn(Founder and Chief Executive Officer)inRachel McMinn, Ph.D.(Founder and Chief Executive Officer)
BoardCory Freedland(Director)inStephen Biggar(Director)
Co-investorsEcoR1 CapitalSamsara BioCapitalCasdin CapitalREDMILEWilliam Blair
Pyxis Oncology is a clinical-stage biotech company developing antibody-drug conjugates for solid tumors, with its lead candidate targeting a fibronectin variant found in tumor tissue but not healthy tissue.
HealthtechBoston, US
Thomas Civik(Interim Chief Executive Officer, Director)
BoardDavid Steinberg(Executive Officer, Director)inChristoph Westphal(Director)Geeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)
Co-investorsAgent CapitalLifeSci Venture PartnersLongwood FundPfizer Venture InvestmentsRA Capital
Stoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.
BiotechBedford, US
Adrian Krainer(Executive Officer, Director, Promoter)Isabel Aznarez(Executive Officer, Director, Promoter)inHuw Nash(Executive Officer)inIan F. Smith(Chief Executive Officer and Director)Jason Hoitt(Chief Patient Officer)inThomas E. Leggett(Chief Financial Officer)
Co-investorsScion Life Sciences5AM Ventures
Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.
BiotechHealthtechMedical Devices
Bobak Azamian, MD, PhD(Founder)inBobak Azamian(President and Chief Executive Officer)inJeffrey Farrow(Chief Financial Officer and Chief Strategy Officer)Seshadri Neervannan(Chief Operating Officer)Aziz Mottiwala(Chief Commercial Officer)inDianne Whitfield(Chief Human Resources Officer)in
Co-investorsAPERTURE Venture PartnersFlying L PartnersFrazier Life SciencesVisionary VenturesVivo CapitalBain Capital Life Sciences+1 more
Offers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.
BiotechMalvern, US
Antony Koblish(Founder)inFrancis Conway(Executive Officer)Maarten Persenaire(Executive Officer)Christine Arasin(Executive Officer)
BoardKevin Rakin(Director)inAshley Freidman(Director)
Co-investorsCheckmate Capital Group LLCEssex Woodlands Healthcare PartnersHighCape CapitalOrbiMedSignet Healthcare Partners1315 Capital
Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.
AI & Machine LearningBiotechHealthtechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)inAnsuman Satpathy(Scientific Founder)inNewman Yeilding(Chief Medical Officer)in
Co-investorsAccess BiotechnologyAndreessen HorowitzGV (Google Ventures)Versant VenturesTPGAccess Industries+1 more
Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.
BiotechDigital HealthMedical Devices
Gaurav Shah(Co-founder & Chief Executive Officer)in
Board seatRoderick WongNaveen Yalamanchi· per SEC Form D · $30.1M raise · filed May 2017
Co-investorsAvoro Capital AdvisorsBroadview VenturesCivilization Ventures Management, LlcFrazier Life SciencesLifeSci Venture Partners
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in
Co-investorsDroia VenturesFrazier Life SciencesNovartis Venture FundFrazier Healthcare PartnersMPM BioImpactThuja Capital
Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease.
BiotechDigital HealthHealthtechMedical DevicesCary, US
Shahid Nimjee(Co-founder, Chief Scientific Officer and Stroke Clinical Lead)inBruce Sullenger(Co-founder)Julia Owens(Executive Officer, Director, Promoter)inRichard Shea(Executive Officer, Director, Promoter)in
BoardHannah Chang(Director)Aiden Aceves(Director)in
Co-investorsARCH Venture PartnersInsight PartnersBroadview VenturesSolas BioVenturesPlatanus VenturesRev1 Ventures
DealForma provides a data platform and analyst support for biopharma business development teams to research partnerships, deals, funding trends, and therapeutic areas.
BiotechData & InfrastructureHealthtechSaaS
Chris
Co-investorsTinySeedAlgerRA CapitalREDMILESofinnova Ventures
Encoded develops gene therapies for neurological disorders through an integrated platform approach.
BiotechSouth San Francisco, US
Stephanie Tagliatela(Co-founder, Chief Scientific Officer & Board Member)inKartik Ramamoorthi, Ph.D.(Co-founder, Chief Executive Officer & Board Member)
Co-investorsARCH Venture PartnersBioBritGV (Google Ventures)Illumina VenturesMenlo VenturesSoftBank Vision Fund+2 more
LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US.
BiotechHealthtechMedical DevicesSan Diego, US
James McCollum(Co-founder, Board Member)Eef SchimmelpenninkinEvert Schimmelpennink(President and CEO)
Co-investorsAlpha Wave GlobalRA CapitalRaptor GroupSectoral Asset ManagementVersant Ventures
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsHBM PartnersBAM ElevateFranklin Templeton+5 more
Magnolia Medical develops diagnostic devices to reduce blood culture contamination and false-positive sepsis test results for hospitals and healthcare systems.
HardwareHealthtechMedical DevicesSeattle, US
Gregory J Bullington(Executive Officer, Director)Richard Patton(Co-founder)
BoardPaul Meister(Director)
Co-investorsEvidity Health CapitalLauder PartnersMarram VenturesRhapsody Venture PartnersVivo CapitalHealthQuest Capital+3 more
Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.
BiotechDigital HealthHealthtechMedical DevicesMontreal, US
Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)
Co-investorsPappas CapitalAmplitude Venture CapitalForbion
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)in
Co-investors5AM VenturesOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalvenBio Global Strategic+1 more
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
David Urech(Founder)in
Co-investorsEisai Innovation, Inc.HBM Healthcare InvestmentsHBM PartnersBiotechnology Value FundBlackRockForbion+1 more
Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer.
BiotechDeep TechHealthtechShanghai, CN
Helen Yang(Founder)inIris Huangin
Co-investorsQiming Venture PartnersVivo CapitalQuan Capital
Serapha Bio is a biotechnology company.
Biotech
Co-investorsRA CapitalVivo Capital
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Co-investorsBlackRockEndeavour VisionMVM Life Science PartnersSoleus CapitalvenBio Global StrategicVivo Capital
Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.
AI & Machine LearningData & InfrastructureDefense TechTel Aviv
Amiad Daniel(Executive Officer, Director)Matan Peled(Director)in
BoardDov Gatmon(Director)Patrick Poon(Director)Eden Shochat(Director)inThompson Hutton(Director)in
Co-investorsAlephFTV CapitalThompson Hutton, LLCJanus Henderson InvestorsPivotal Life SciencesQiming Venture Partners+3 more
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedQuan CapitalRA CapitalSanofi VenturesSR One Capital ManagementJanus Henderson Investors+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Attune PharmaceuticalsAmani TherapeuticsCORXEL PharmaceuticalsIkena Oncology, Inc.iTeos TherapeuticsMagnolia MedicalSmall MoleculesYarrow
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 11
11 IPOsAktis OncologyNASDAQ: AKTSApogee TherapeuticsNASDAQ: APGEAquestive TherapeuticsNASDAQ: AQSTBeta Bionics, IncNASDAQ: BBNXKalaris Therapeutics, Inc.NASDAQ: KLRSKyverna TherapeuticsNASDAQ: KYTXNeurogeneNASDAQ: NGNEPyxis OncologyNASDAQ: PYXSStoke TherapeuticsNASDAQ: STOKTarsus PharmaceuticalsNASDAQ: TARSTELA BioNASDAQ: TELA
Portfolio news
latest coverage across their companiesDealForma · dealforma.com · Feb 6, 2026
IPO stake values · per SEC filings · 7
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Apogee Therapeutics | 3.7% | $62.00 | Mar 2024 | $132.8M |
| Beta Bionics, Inc | 7.2% | $17.00 | Jan 2025 | $52.7M |
| Stoke Therapeutics | 8.9% | $18.00 | Jun 2019 | $50.4M |
| Kyverna Therapeutics | 3.4% | $22.00 | Feb 2024 | $30.9M |
| Pyxis Oncology | 4.4% | $16.00 | Oct 2021 | $23.1M |
| TELA Bio | 8.9% | $16.00 | Jun 2020 | $20.6M |
| Tarsus Pharmaceuticals | 5.5% | $16.00 | Oct 2020 | $17.1M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has RTW Investments L.P. made?
- RTW Investments L.P. has 36 tracked investments, 11 of which have exited, including 9 dated in the last 24 months.
- What stage does RTW Investments L.P. invest at?
- RTW Investments L.P. invests at the Seed, Series A stages.
- What sectors does RTW Investments L.P. focus on?
- RTW Investments L.P. focuses on Biotech.
- Where is RTW Investments L.P. located?
- RTW Investments L.P. is headquartered in New York, US.
Co-investors · 7
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Qiming Venture Partners (启明创投) is a China-focused venture capital firm that invests in and supports early- and growth-stage technology and healthcare companies, providing capital, industry resources, and strategic guidance through milestones such as financing, IPOs, and M&A.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Domain Associates is a venture capital firm founded in 1985 that invests in life sciences companies. The firm operates as a limited liability company.
Firms observed investing alongside RTW Investments L.P., from public investor directories. Shared companies are the overlap with RTW Investments L.P.'s recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.